甲磺酸伊马替尼治疗可减轻慢性粒细胞白血病患者的骨髓纤维化。

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

作者信息

Bueso-Ramos Carlos E, Cortes Jorge, Talpaz Moshe, O'Brien Susan, Giles Francis, Rios Mary Beth, Medeiros L Jeffrey, Kantarjian Hagop

机构信息

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

出版信息

Cancer. 2004 Jul 15;101(2):332-6. doi: 10.1002/cncr.20380.

DOI:10.1002/cncr.20380

PMID:15241831

Abstract

BACKGROUND

Reticulin-stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome.

METHODS

The effect of imatinib therapy on bone marrow fibrosis was evaluated in 40 patients with chronic-phase CML who were treated after interferon-alpha failure.

RESULTS

Thirty-one patients (78%) had severe (Grade 3 or 4) reticulin fibrosis prior to therapy. After imatinib therapy was administered for 3 to > 24 months, fibrosis was reduced by at least 2 grades in 19 of the 31 patients (61%) and by at least 1 grade in 34 patients (85%). There was no correlation noted between reduction of fibrosis and cytogenetic response. However, a reduction in fibrosis was found to correlate with a reduction in bone marrow megakaryocytosis (P = 0.002).

CONCLUSIONS

Treatment with imatinib mesylate appears to reduce CML-associated bone marrow fibrosis in most patients who are treated during the chronic phase of disease. This effect may be independent of the degree of suppression of Philadelphia chromosome-positive cells, and may improve prognosis in patients with CML.

摘要

背景

网硬蛋白染色的骨髓纤维化与慢性粒细胞白血病（CML）患者的不良预后相关。治疗后纤维化的消退可能改善患者预后。

方法

在40例α干扰素治疗失败后接受治疗的慢性期CML患者中评估伊马替尼治疗对骨髓纤维化的影响。

结果

31例患者（78%）在治疗前有严重（3级或4级）网硬蛋白纤维化。在给予伊马替尼治疗3至超过24个月后，31例患者中有19例（61%）纤维化程度至少降低2级，34例患者（85%）纤维化程度至少降低1级。未发现纤维化程度降低与细胞遗传学反应之间存在相关性。然而，发现纤维化程度降低与骨髓巨核细胞增多症的减轻相关（P = 0.002）。